Events & News
Catch up with the latest news about Demeetra and our technologies. Plus, find out where you can next connect with the Demeetra Team.
More coming soon!
ERS Genomics & Demeetra Enter Into CRISPR/Cas9 Licensing Agreement
Dublin, Ireland and Kentucky, USA, September 12: ERS Genomics Limited (‘ERS’) is pleased to announce a new license agreement with Demeetra AgBio (‘Demeetra’). This is a non-exclusive licensing agreement granting Demeetra access to the ERS CRISPR/Cas9 patent portfolio which is sublicensable when combined with Cas-CLOVER.
Seamlessly Upgrade Your CRISPR Toolbox From Cas9 to Cas-CLOVER™
Over a decade ago, Cas9 came on the scene as the first RNA-guided nuclease, simplifying and expanding the use of gene editing. But now it’s time for an upgrade in performance and economy. Single RNA-guided Cas9 yields high off-target mutation frequencies, which often result in disruptions to product development. The small blunt-ended genomic deletions created…
Gene Editing May Soon Be Rolling in Clover
The early CRISPR-Cas9 gene editing systems didn’t lack for brashness. They quickly set new standards for economy and ease of use. They even seemed to offer high degrees of accuracy and efficiency. But soon, brashness started to show its limits. What was needed in its place was refinement. Possible alternatives to CRISPR-Cas9 included a transposase…
The Greatest Gene Editing Technology on the Planet?
As published in GEN Magazine. Cas-CLOVER significantly reduces off-target risk with a paired gRNA, deactivated Cas fusion protein (dCas), and dimeric Clo051 nuclease. A proven technology for cell line development (CLD) and bioprocessing, agriculture, and synthetic biotechnology, Cas-CLOVER also features high efficiency in target cells and organisms coupled with simple and flexible design and technology…